Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


A more recent version of this article appeared on November 1, 2007

Papers In Press, published online ahead of print August 10, 2007
J. Lipid Res., doi:10.1194/jlr.M700170-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M700170-JLR200v1
48/11/2411    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buono, C.
Right arrow Articles by Kruth, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buono, C.
Right arrow Articles by Kruth, H. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on April 5, 2007
Revised on July 24, 2007
Accepted on August 10, 2007

Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL

Chiara Buono, Yifu Li, Stephen W. Waldo, and Howard S. Kruth

Section of Experimental Atherosclerosis, NHLBI, NIH, Bethesda, Maryland 20892-1422

Corresponding Author: kruthh{at}nhlbi.nih.gov

Liver X receptors (LXRs) are ligand-activated transcription factors involved in the control of lipid metabolism and inflammation. Several studies have recently shown that LXRs promote reverse cholesterol transport and inhibit atherosclerosis. Our study investigated whether LXRs affect macrophage uptake of LDL by human monocyte-derived macrophages. We have previously shown that human monocytes differentiated into macrophages with macrophage-colony-stimulating factor (M-CSF) constitutively take up large amounts of native LDL by receptor-independent, fluid-phase pinocytosis. In the research reported here, human monocytes were differentiated to macrophages in the presence of M-CSF with or without the LXR agonists, T0901317 or 22(R)-hydroxycholesterol. Then, macrophages were incubated with native 125I-LDL to determine LDL uptake. T0901317 and 22(R)-hydroxycholesterol inhibited 125I-LDL uptake by 68 ± 1% and 69 ± 2%, respectively, and decreased pinocytotic vacuoles in the macrophages. 125I-BSA uptake, a measure of fluid-phase pinocytosis, and 125I-LDL uptake were the same and T0901317-treatment inhibited uptake of both to the same degree. T0901317 did not affect receptor-mediated uptake of acetylated LDL showing that the LXR effect is specific for fluid-phase pinocytosis of lipoproteins. In conclusion, our results show that LXRs downregulate macrophage pinocytosis of LDL. The findings reveal an additional new mechanism by which LXR agonists may inhibit macrophage cholesterol accumulation and atherosclerosis, namely by inhibiting macrophage uptake of LDL.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
S. W. Waldo, Y. Li, C. Buono, B. Zhao, E. M. Billings, J. Chang, and H. S. Kruth
Heterogeneity of Human Macrophages in Culture and in Atherosclerotic Plaques
Am. J. Pathol., April 1, 2008; 172(4): 1112 - 1126.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement